Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06959524 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

StatusRecruiting
PhaseNot applicable
Started2025-08-21
View on ClinicalTrials.gov ↗

Amendment history

2026-08-26
minor
Study Status, Eligibility, Contacts/Locations v22
Study sites67→68
Eligibility criteria+243 characters
[...] sion is a de novo lesion located in a native coronary artery. Target lesion must have visually estimated stenosis > 50% a [...] s with substance abuse (e.g. alcohol, cocaine, heroin, etc.) as assessed by Investigator. Subject has planned procedure that may cause non-complianc [...] ect has left ventricular ejection fraction known to be < 30% within the last 12 months. Subject had PCI or other coronary interventions within the last 303 days. Subject has planned PCI or CABG after the index proce [...] MI <72h prior to the index procedure. Subject presents with NSTEMIACS and rising biomarkers, or ongoing chest pain o [...] [...]
2026-07-29
minor
Study Status, Contacts/Locations v21
Trial sites expanded: 62 → 67 locations
2026-07-01
minor
Study Status, Contacts/Locations v20
Trial sites expanded: 55 → 62 locations
2026-06-02
minor
Study Status, Contacts/Locations v19
Trial sites expanded: 50 → 55 locations
2026-05-06
minor
Study Status, Contacts/Locations v18
Trial sites expanded: 46 → 50 locations
2026-04-27
minor
Study Status, Contacts/Locations v17
Study sitescontacts updated at 1 of 46 sites
2026-04-16
minor
Study Status, Contacts/Locations v16
Trial sites expanded: 41 → 46 locations
2026-03-24
minor
Study Status, Contacts/Locations v15
Study sites35→41
2026-02-23
minor
Study Status, Contacts/Locations v14
Study sites30→35
2026-02-11
minor
Study Status, Contacts/Locations v13
Study sites27→30
2026-02-03
minor
Study Status, Contacts/Locations v12
Study sites22→27
2026-01-05
minor
Study Status, Contacts/Locations v11
Study sites18→22
2025-12-04
minor
Study Status, Contacts/Locations v10
Study sites8→18
2025-11-05
minor
Study Status, Contacts/Locations v9
Study sites1→8
2025-10-17
minor
2 amendments v7-v8
2 re-verifications since 2025-10-02, no change to tracked fields
2025-09-04
notable
Not Yet Recruiting→Recruiting Study Status, Conditions, Contacts/Locations v6
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-09→confirmed 2025-08-21
Study sites0→1
2025-08-09
minor
Study Status, Study Design v5
Enrollment target1328→1616
2025-07-16
minor
4 amendments v1-v4
4 re-verifications since 2025-05-29, no change to tracked fields
2025-05-05
minor
Original filing
AGENT DCB STANCE is a prospective, multicenter, open-label, 1:1 randomized controlled study designed to assess the safety and effectiveness of a treatment strategy with the AGENT Drug-Coated Balloon compared to standard of care percutaneous coronary intervention (PCI) treatment with drug eluting stent (DES) and/or balloon angioplasty in patients with de novo coronary lesions. Subjects must have a de novo target lesion located in a native coronary artery.
Trial Details
NCT Number NCT06959524
Lead Sponsor Boston Scientific Corporation
Conditions Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Enrollment 1,616 participants
Start Date 2025-08-21
Primary Completion 2028-03 (estimated)
Study Completion 2032-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-29